UPDATED: Melinta’s CEO steps down amid a big Phase III push

Damian Garde Melinta Therapeutics CEO Mary Szela has left the company in the middle of a late-stage program for its lead antibiotic, a move that comes just months after the biotech ...

European pharma lobby says ‘non’ to French funding for off-label Avastin

Emily Wasserman The French government recently said "oui" to Roche's ($ RHHBY) cancer drug Avastin as a cheap, off-label treatment for the blinding eye disease wet age-related ...

Alnylam, Medicines Co. say next-gen PCSK9 drug has blockbuster potential

John Carroll FierceBiotech News

Takeda rolls toward EU approval with its heir to Velcade

Damian Garde Takeda's top oncology prospect is moving toward approval in the European Union, as continental regulators have accepted the company's application and promised a ...

Ackman’s Valeant ties pay off yet again with Sprout buy

Carly Helfand Bill Ackman's relationship with Valeant has paid off big-time since the hedge fund manager first teamed up with the Canadian pharma on its hostile pursuit of Allergan. ...

Proxy adviser ISS slams Mylan’s Perrigo bid, flagging ‘unreasonable uncertainties’

Carly Helfand On Wednesday, a pair of proxy advisers recommended that Mylan shareholders support the company's quest to bag Irish target Perrigo. But not ISS. FiercePharma News

GSK says people and products were never in danger from Legionella bacteria in cooling towers

Eric Palmer GlaxoSmithKline says that the people and products at its manufacturing site in Zebulon, NC, were never in peril from the bacteria for Legionnaires' disease detected ...

Post-Sarepta, Art Krieg gets $20M to take a shot at an immuno-oncology Checkmate

John Carroll A year after getting bounced from a turbulent Sarepta, Art Krieg is prepping for his next act in biotech, snatching a failed lead immunology drug from the dying, Zurich-based ...

Cold Genesys looks to China for a $10M cash infusion

Damian Garde Immuno-oncology biotech Cold Genesys raised a $ 10 million B round, rallying a stable of Chinese financiers as it moves forward with a late-stage cancer therapy. FierceBiotech ...

With $300M spent on potential split, Pfizer CEO now ‘biased’ toward branded M&A

Tracy Staton Now that Hospira's in the bag, Pfizer execs have less of an appetite for M&A in their Established Products unit. That $ 16 billion deal gives Pfizer added heft ...

Baxalta to Shire: We’re young, we’re just starting to grow, and we’re rejecting your buyout offer

Carly Helfand On Tuesday, Shire went public with a $ 30 billion bid for Baxalta that had already been rejected once. And the second time around, Baxalta had the same answer: It's ...

EyeGate ekes out a tiny IPO to fund its R&D efforts

Damian Garde Massachusetts' EyeGate Pharmaceuticals picked up $ 10 million in an IPO do-over, raising cash to support its sole clinical candidate. FierceBiotech News
Page 5 of 129« First...34567...102030...Last »
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS